Impairment of antigen-specific antibody production in transgenic mice expressing a dominant-negative form of gp130.
about
RETRACTED: Silencing of B cell receptor signals in human naive B cells.gp130 at the nexus of inflammation, autoimmunity, and cancer.A role for IL-27p28 as an antagonist of gp130-mediated signaling.Priming microenvironments dictate cytokine requirements for T helper 17 cell lineage commitment.Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantationThe induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cellsProstaglandin F2α inhibits adipogenesis via an autocrine-mediated interleukin-11/glycoprotein 130/STAT1-dependent signaling cascade.STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroiInterleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component.The expression of IL6 and 21 in crossbred calves upregulated by inactivated trivalent FMD vaccine.Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells.Endothelin-1 induces expression of fetal genes through the interleukin-6 family of cytokines in cardiac myocytes.gp130 plays a critical role in pressure overload-induced cardiac hypertrophy.Signal TransductionThrough Cytokine ReceptorsClass-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4 T Cell-Independent CD8 T-Cell Response Against Unconjugated Protein Antigen
P2860
Q34159611-5FAE338C-D614-4B64-B4BF-2EDAA2BFF6F2Q34378756-09F845B3-D580-48D8-A13F-E67AD7999D9CQ34688139-8F6DF8FB-D1EE-4AB6-833A-FE2BAADE9A55Q35633994-BCC9B754-9858-4E2C-810F-24580DA4843EQ36369420-45FD461A-922E-40EA-B796-FE451C52E738Q37061850-D9EC793A-127F-4FD2-A707-469960A28585Q39024718-5373BC8E-8BD8-4352-8F73-BA924DB9BD75Q40945774-E63785BB-42DC-41E0-876B-C85D7390A774Q41839042-DBC6B715-C320-495B-9A74-6BB6F78A6E2EQ42236079-37F65F66-72FD-45F2-B4C5-0E10B84A9228Q42741704-47D96500-CC6D-4220-B1DC-4EA108F7D4BDQ48132886-C1793EDC-13E5-4AA1-B639-8603A6A6CA15Q48944371-A80DD46E-5F31-4C54-BB69-697CB3718360Q58173667-F093E4D0-7E84-4FCE-9297-99406BE8FFD6Q58575827-CFF5256A-6547-4359-8936-410AAB1B0999
P2860
Impairment of antigen-specific antibody production in transgenic mice expressing a dominant-negative form of gp130.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Impairment of antigen-specific ...... minant-negative form of gp130.
@ast
Impairment of antigen-specific ...... minant-negative form of gp130.
@en
type
label
Impairment of antigen-specific ...... minant-negative form of gp130.
@ast
Impairment of antigen-specific ...... minant-negative form of gp130.
@en
prefLabel
Impairment of antigen-specific ...... minant-negative form of gp130.
@ast
Impairment of antigen-specific ...... minant-negative form of gp130.
@en
P2093
P2860
P356
P1476
Impairment of antigen-specific ...... minant-negative form of gp130.
@en
P2093
A Kumanogoh
S Marukawa
T Kishimoto
T Kumanogoh
P2860
P304
P356
10.1073/PNAS.94.6.2478
P407
P577
1997-03-01T00:00:00Z